Medical Management of Brain Metastases from Lung Cancer

Ryuya Yamanaka

Kyoto Prefectural University of Medicine
Graduate School for Health Care Science, Kamigyoku, Kyoto
Japan

1. Introduction

Brain metastases are a frequent complication in patients with lung cancer and a significant cause of morbidity and mortality. Brain metastases are found in about 10-25% of patients at the time of diagnosis, and approximately 40-50% of all patients with lung cancer develop brain metastases during the course of their disease, with greater frequency at autopsy (approximately 50%) than predicted from the presence of symptoms (1). The incidence of brain metastasis is increasing mainly due to longer patient survivals resulting from newer treatment modalities. Most patients with lung cancer metastatic to the brain have multiple lesions (2). Brain metastases are usually associated with poor outcomes and shortened survival of 3 to 6 months. Standard treatment options include symptomatic therapy with corticosteroids and whole-brain radiotherapy (WBRT) (3), and more aggressive approaches such as surgery or radiosurgery are indicated in a subset of patients (4,5). Surgical resection of accessible brain metastases combined with postoperative WBRT is the management of choice for a single metastasis (6). However, radiosurgery for brain metastases produces high rates of tumor control similar to the rates obtained by excisional surgery (7). Patients with multiple brain metastases are commonly treated with WBRT for the palliation of symptoms (8). The role of radiosurgery for multiple brain metastases is less clear, but it can be effective (9). The poor outcomes and relapses following WBRT alone indicate a need for new therapeutic options. Generally, poor prognosis occurs not from cerebral problems, but from extracranial metastases, and death is caused by systemic disease combined with the neurological condition (10). However, treatment with systemic chemotherapy is controversial because chemotherapeutic agents may not cross the blood-brain-barrier (BBB) and therefore are less effective against central nervous system (CNS) disease than against extracranial, systemic disease. However, the BBB is partially disrupted in brain metastases (11) and similar concentrations of chemotherapeutic agents are found in intracerebral and extracerebral tumors (5). Brain metastases resulting from both non-small-cell (NSCLC) and small-cell lung cancer (SCLC) are susceptible to systemic chemotherapy, and cerebral response rates up to 50% were observed even in second-line treatment of NSCLC and SCLC (1,10,11). Still, medical therapies for brain metastases are neither well-studied nor established. Here, I analyze the impact of medical treatment on survival by reviewing recent articles and provide recommendations for the management of patients with brain metastases from lung cancer.
2. Non-small cell lung cancer (NSCLC)

NSCLC accounts for approximately 75% of lung cancer cases, with the majority of patients having inoperable, locally advanced or metastatic disease at the time of diagnosis, reflected in the low 5-year survival rate for all stages (currently 13%) (12). Despite two decades of cisplatin-based chemotherapy of advanced NSCLC, the survival benefit remains modest (13). New chemotherapy combinations have minimal impact on survival compared with older regimens, with overall response rates of approximately 30%, median survival benefits of 8–9 months, and 1-year survival rates of approximately 30% (14). New therapies are required that are effective against locally advanced or metastatic NSCLC.

2.1 Front-line chemotherapy (Table 1)

Many chemotherapeutic regimens have been tested in phase II or III trials for the treatment of brain metastases arising from NSCLC. There are 8 larger reports (15-22) with more than 10 patients, published from 1994 to 2008 in English, on front-line chemotherapy of brain metastases from NSCLC. In patients with NSCLC, 17-50% of patients with previously untreated brain metastases responded to a combination of cisplatin plus fotemustine; carboplatin plus etoposide; cisplatin plus teniposide; cisplatin plus etoposide; cisplatin plus ifosfamide, CPT-11; cisplatin plus vinorelbine; carboplatin plus vinorelbine, gemcitabine; cisplatin plus paclitaxel. Systemic disease activity correlates well with activity against brain metastases, but overall survival (OS) is still 4-12 months.

<table>
<thead>
<tr>
<th>Author</th>
<th>Regimen</th>
<th>No. of patients</th>
<th>Study design</th>
<th>Response rate (%)</th>
<th>Disease stabilization (%)</th>
<th>mPFS (Month)</th>
<th>OS (Month)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cotto C</td>
<td>CDDP,Fotemustine</td>
<td>31</td>
<td>Phase II</td>
<td>23</td>
<td>51.6</td>
<td>5</td>
<td>4</td>
</tr>
<tr>
<td>Malacarne P</td>
<td>CBDCA,VP16</td>
<td>18</td>
<td>Phase II</td>
<td>17</td>
<td>39</td>
<td>n.d.</td>
<td>7.5</td>
</tr>
<tr>
<td>Minotti V</td>
<td>CDDP,Teniposide</td>
<td>23</td>
<td>Phase II</td>
<td>35</td>
<td>65</td>
<td>7</td>
<td>5</td>
</tr>
<tr>
<td>Franciosi V</td>
<td>CDDP,VP-16</td>
<td>43</td>
<td>Phase II</td>
<td>30</td>
<td>65</td>
<td>4</td>
<td>8</td>
</tr>
<tr>
<td>Fujita A</td>
<td>CDDP,IFOS,CPT-11</td>
<td>28</td>
<td>Phase I/II</td>
<td>50</td>
<td>96</td>
<td>4.6</td>
<td>12</td>
</tr>
<tr>
<td>Robinet G</td>
<td>CDDP,VNR</td>
<td>76</td>
<td>Phase III</td>
<td>27</td>
<td>n.d.</td>
<td>3.2</td>
<td>6</td>
</tr>
<tr>
<td>Bernardo G</td>
<td>CBDCA,VNR,GEM</td>
<td>22</td>
<td>Phase II</td>
<td>45</td>
<td>85</td>
<td>6.2</td>
<td>8.2</td>
</tr>
<tr>
<td>Cortes J</td>
<td>CDDP,Paclitaxel</td>
<td>26</td>
<td>Phase II</td>
<td>38</td>
<td>69</td>
<td>3.2</td>
<td>5.3</td>
</tr>
</tbody>
</table>

Table 1.CBDCA,carboplatin; CDDP, cisplatin; CPT-11, irinotecan; GEM, gemcitabine; IFOS, ifosfamide; mOS, median overall survival; mPFS, median progression free survival; n.d., not determined; VNR, vinorelbine; VP16, etoposide. Modified from: Yamanaka R. Oncol Rep 2009;22:1269-1276 with permission from Spandidos Publications
2.2 Second-line chemotherapy
2.2.1 Epidermal growth factor receptor tyrosine kinase Inhibitor
The epidermal growth factor receptor (EGFR) is expressed in a variety of tumors, including NSCLC (23), and elevated EGFR expression is associated with a poor prognosis in lung cancer patients (24). Several EGFR-targeted agents have been developed, including gefitinib (ZD1839; Iressa) and erlotinib (OSI-774; Tarceva), an orally active anilinoquinazoline compound that inhibits EGFR tyrosine kinase activity (25). In two large, well-designed phase II clinical trials, refractory patients with NSCLC experienced overall response rates of 11.8–18.4%, median survival benefits of 6.5–7.6 months, and 1-year survival rates of 29–35% (26,27), with encouraging response rates in select patients (women, non-smokers, patients with adenocarcinoma, and specific EGFR mutations in the kinase domain) (28-33). Although targeting EGFR-associated tyrosine kinase with gefitinib and erlotinib results in durable responses in some patients, the activity of these drugs against brain metastases has been poorly documented so far.

Gefitinib (Table 2)
Phase II studies of gefitinib on brain metastases from NSCLC indicated objective responses occur in 33% of patients (Asia) (34,35) or 9.7% of patients (Europe) (36). In comparison, WBRT with 30 to 40 Gy for brain metastases from NSCLC results in objective responses in 38% to 45% of patients (37,38). Gefitinib is well tolerated, mostly with grade 1/2 skin rashes. The severity of skin toxicity was tightly associated with tumor response and patient survival (34). Gefitinib was most effective at treating brain metastases in patients with EGFR mutations in the tyrosine kinase domain (deletion mutation in two patients and a point mutation in one patient) in one study (39). However, this analysis was performed using tissue samples from primary lung cancer and not from metastatic brain lesions. Yokouchi et al. (40) reported that some patients who experienced disease progression after responding to gefitinib were sensitive to gefitinib re-administration after temporary cessation of gefitinib and other treatments. Patients may still be expected to have prolonged survival if they once responded to gefitinib and then underwent various subsequent treatments followed by re-administration of gefitinib. These findings might provide valuable information for the management of gefitinib-responders. Although the survival benefit is controversial, gefitinib may also be useful for the treatment of carcinomatous meningitis from NSCLC to improve neurological dysfunction (41,42,43). Thus, gefitinib has therapeutic potential for palliative therapy in patients with brain metastases.

<table>
<thead>
<tr>
<th>Author</th>
<th>No. of patients</th>
<th>Study design</th>
<th>Previous WBRT/Chemo (%)</th>
<th>Response rate (%)</th>
<th>Disease stabilization (%)</th>
<th>mPFS (Month)</th>
<th>OS (Month)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ceresoli GL</td>
<td>41</td>
<td>phase II</td>
<td>43.9/90.2</td>
<td>9.7</td>
<td>26.8</td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td>Chiu CH</td>
<td>76</td>
<td>phase II</td>
<td>n.d./84.2</td>
<td>33.3</td>
<td>63.2</td>
<td>5</td>
<td>9.9</td>
</tr>
<tr>
<td>Wu C</td>
<td>40</td>
<td>phase II</td>
<td>65/100</td>
<td>32</td>
<td>77</td>
<td>9</td>
<td>15</td>
</tr>
</tbody>
</table>

Table 2. Chemo, chemotherapy; mOS, median overall survival; mPFS, median progression free survival; n.d., not determined; WBRT, whole brain radiotherapy. Modified from: Yamanaka R. Oncol Rep 2009;22:1269-1276 with permission from Spandidos Publications.
Erlotinib treatment of brain metastases from NSCLC has been reported in 20 cases (44-55). These were histologically confirmed as adenocarcinoma in the primary site. The main adverse events were Grade 1 skin rashes. Some patients had responses longer than 6 months. Erlotinib responses are higher in patients with a somatic mutation in EGFR or a point mutation in the activation loop of the kinase domain (56,57). Thirteen patients showed a response to erlotinib after gefitinib failure. Although gefitinib failure may result from cross-resistance to other EGFR tyrosine kinase inhibitors (EGFR-TKI), these cases suggest that re-challenging patients with EGFR-TKI may be beneficial. At the recommended dosage, erlotinib showed higher blood concentrations than gefitinib, and may also have higher in cerebral spinal fluid. In addition, two patients with intracranial lesions responded to erlotinib treatment although extra-cranial lesion progressed. In the Rupper case (51), a secondary T790M mutation associated with resistance to EGFR-TKI was found in the liver biopsy. Erlotinib was reintroduced and produced quick neurological improvement, even though the extra-cranial disease remained resistant to erlotinib. These cases also highlight the oligoclonal nature of NSCLC and its differential sensitivity to EGFR-TKIs, in that extra-cranial disease was resistant to erlotinib both initially and on re-challenge. Persistent cerebral TKI sensitivity should be considered in patients presenting with a CNS relapse after stopping EGFR-TKI, even with a T790M resistant mutation in non-cerebral metastases. In addition, erlotinib should be considered for treatment of intra-cranial disease.

2.2.2 Temozolomide (Table 3)
Temozolomide is an orally administered prodrug that is converted spontaneously to the active alkylating agent, monomethyl triazenoimidazole carboxamide, at physiologic pH, crosses the BBB, and has antitumor activity against malignant glioma, melanoma, NSCLC, and carcinoma of the ovary and colon (58). CNS concentrations reach approximately 30–40% of plasma levels, achieving therapeutic concentrations in the brain (59), and clearance of temozolomide is unaffected by co-administration with anticonvulsants, antiemetics, or dexamethasone (58,59). The dose-limiting toxicity is non-cumulative myelosuppression that rarely requires treatment delays or dose reductions. In patients with newly-diagnosed brain metastases or with progression after radiotherapy, temozolomide produces objective response rates between 5 and 10% (60-62) and is well tolerated.

<table>
<thead>
<tr>
<th>Author</th>
<th>Regimen</th>
<th>No. of patients</th>
<th>Study design</th>
<th>Previous WBRT/Chemo (%)</th>
<th>Response rate (%)</th>
<th>Disease stabilization (%)</th>
<th>mPFS (Month)</th>
<th>OS (Month)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Giorgio</td>
<td>TMZ</td>
<td>30</td>
<td>phase II</td>
<td>100/100</td>
<td>10</td>
<td>20</td>
<td>3.6</td>
<td>6</td>
</tr>
<tr>
<td>Kouroussis C</td>
<td>TMZ</td>
<td>12</td>
<td>phase II</td>
<td>n.d./100</td>
<td>8.3</td>
<td>25</td>
<td>n.d.</td>
<td>n.d.</td>
</tr>
<tr>
<td>Abrey LE</td>
<td>TMZ</td>
<td>22</td>
<td>phase II</td>
<td>100/n.d.</td>
<td>9</td>
<td>45</td>
<td>n.d.</td>
<td>n.d.</td>
</tr>
<tr>
<td>Christodoulou C</td>
<td>TMZ</td>
<td>12</td>
<td>phase II</td>
<td>100/n.d.</td>
<td>8</td>
<td>n.d.</td>
<td>n.d.</td>
<td>n.d.</td>
</tr>
</tbody>
</table>

Table 3. TMZ, temozolomide; Chemo, chemotherapy; mOS, median overall survival; mPFS, median progression free survival; n.d., not determined; WBRT, whole brain radiotherapy. Modified from: Yamanaka R. Oncol Rep 2009;22:1269-1276 with permission from Spandidos Publications.
2.2.3 Temozolomide plus other chemotherapeutic agents

Preclinical experiments and early clinical studies in other malignancies indicate that temozolomide may have additive or synergistic effects when used with other chemotherapeutic agents (64,65). In addition, its minimal toxicity allows for the combination of temozolomide with gemcitabine, gemcitabine/cisplatin, or gemcitabine/vinorelbine in NSCLC patients to produce dramatic cerebral responses (66,67). The combination of temozolomide with other chemotherapeutic agents represents a promising strategy for treating brain metastases.

2.3 Chemotherapy plus whole-brain irradiation (Table 4)

Combining chemotherapy with brain radiotherapy is attractive because chemotherapy is active against both primary tumors and brain metastases, and because chemotherapy may act as a radiosensitizer. Two studies have compared randomized chemotherapy alone with chemotherapy/WBRT. Quantin et al. (68) reported a phase II study of radiotherapy plus vinorelbine, ifosfamide, and cisplatin chemotherapy in patients with brain metastases of NSCLC. The response rate was 56% and median survival was 7.6 months. The same author also reported a phase II study with concomitant brain radiotherapy and high-dose ifosfamide in brain relapses (69). Median survival was 13 months. Myelosuppression was the main toxic effect, but remained manageable and no toxic deaths occurred. The high response rate for brain lesions and improvement in neurological symptoms deserves further exploration.

<table>
<thead>
<tr>
<th>Author</th>
<th>Chemotherapy Regimen</th>
<th>No. of patients</th>
<th>Study design</th>
<th>Previous WBRT/Chemo (%)</th>
<th>Response rate (%)</th>
<th>Disease stabilization (%)</th>
<th>mPFS (Month)</th>
<th>OS (Month)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quantin</td>
<td>CDDP,VNR, IFOS</td>
<td>23</td>
<td>phase II</td>
<td>0/0</td>
<td>56</td>
<td>65</td>
<td>n.d.</td>
<td>7.6</td>
</tr>
<tr>
<td>Quantin</td>
<td>high-dose IFOS</td>
<td>16</td>
<td>phase II</td>
<td>n.d./n.d.</td>
<td>25</td>
<td>n.d.</td>
<td>n.d.</td>
<td>13</td>
</tr>
<tr>
<td>Ma S</td>
<td>Gefitinib</td>
<td>25</td>
<td>phase II</td>
<td>0/0</td>
<td>81</td>
<td>95.2</td>
<td>10</td>
<td>13</td>
</tr>
<tr>
<td>Addeo R</td>
<td>TMZ</td>
<td>15</td>
<td>phase II</td>
<td>44/74</td>
<td>6.5</td>
<td>60</td>
<td>6</td>
<td>8.8</td>
</tr>
<tr>
<td>Cortot</td>
<td>CDDP,TMZ</td>
<td>50</td>
<td>phase II</td>
<td>6/n.d.</td>
<td>12</td>
<td>54</td>
<td>2.3</td>
<td>5</td>
</tr>
<tr>
<td>Robinet</td>
<td>CDDP,VNR</td>
<td>85</td>
<td>phase III</td>
<td>0/0</td>
<td>28</td>
<td>n.d.</td>
<td>2.7</td>
<td>5.2</td>
</tr>
</tbody>
</table>

Table 4. CDDP, cisplatin; Chemo, chemotherapy; IFOS, ifosfamide; mOS, median overall survival; mPFS, median progression free survival; n.d., not determined; TMZ, temozolomide; VNR, vinorelbine; WBRT, whole brain radiotherapy. Modified from: Yamanaka R. Oncol Rep 2009;22:1269-1276 with permission from Spandidos Publications

Ma et al. (70) found that treatment with concomitant gefitinib and WBRT was well tolerated, with significant improvement of neurological symptoms in a Chinese population with brain metastases from NSCLC. Addeo et al. (71) reported response rates of 6.5% using a combination of temozolomide and WBRT. Cortot et al. (72) reported response rates of 12% with temozolomide, cisplatin, and WBRT. A randomized phase II study evaluated the efficacy of concurrent temozolomide and radiotherapy versus radiotherapy alone in 58
patients with previously untreated brain metastases from different solid tumors (31 patients had NSCLC) (73). The temozolomide group showed significant improvements in cerebral response rate (96% versus 67%), and temozolomide was safe and well-tolerated. However, overall survival rates and changes in neurological function were similar in both groups. Robinet et al. (74) reported a phase III study comparing the timing of WBRT, either before or after chemotherapy, and found a 28% response rate in 85 patients treated with cisplatin and vinorelbine in the early WBRT arm. The median survival in this arm was 5.2 months and median time to progression (TTP) was 2.1 months. Radiotherapy timing did not change survival time. Thus, for NSCLC, WBRT should be added to initial chemotherapy if there is no treatment response.

3. Small Cell Lung Cancer

The brain is the most common metastatic site in SCLC, and is usually fatal. Approximately 18-25% of SCLC patients have brain metastases already at diagnosis, and an additional 50% will develop CNS involvement during their disease course (75-77). Although WBRT and corticosteroids are the treatment of choice, systemic chemotherapy may also have therapeutic value. Extracranial disease is almost always present in SCLC, and chemotherapy can treat both brain metastases and these other disease sites. Prophylactic cranial irradiation (PCI) for patients responsive to induction therapy markedly reduces the risk of CNS relapse and significantly improves survival (77,78). Surgical treatment for solitary lesions or systemic chemotherapy for multifocal brain metastases that are minimally symptomatic can be useful, particularly when these patients also have extracranial metastatic disease. Thus, systemic chemotherapy can complement WBRT for treatment of brain metastases in SCLC.

3.1 Front-line chemotherapy (Table 5)

There are 4 larger reports (79-82) with more than 10 patients, published from 1989 to 2008 in English, on front-line chemotherapy of brain metastases from SCLC. The chemotherapeutic regimens, including cyclophosphamide, vincristine, etoposide, doxorubicin and cisplatin, produced response rates of 27-82% Thus, chemotherapy followed by radiation therapy may be first-line treatment for patients with systemic disease and asymptomatic brain metastases.

<table>
<thead>
<tr>
<th>Author</th>
<th>Regimen</th>
<th>No. of patients</th>
<th>Study design</th>
<th>Response rate (%)</th>
<th>Disease stabilization (%)</th>
<th>mPFS (Month)</th>
<th>OS (Month)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lee JS</td>
<td>CTX,DX,VCR,VP-16</td>
<td>11 Phase II</td>
<td>82</td>
<td>91</td>
<td>6</td>
<td>8.5</td>
<td></td>
</tr>
<tr>
<td>Twelves CJ</td>
<td>CTX,VP-16,VCR</td>
<td>25 Retrospective</td>
<td>53</td>
<td>n.d.</td>
<td>5.5</td>
<td>8.5</td>
<td></td>
</tr>
<tr>
<td>Kristjansen PE</td>
<td>CDDP,VP-16,VCR</td>
<td>21 Phase II</td>
<td>52</td>
<td>57</td>
<td>4.5</td>
<td>3.7</td>
<td></td>
</tr>
<tr>
<td>Seute T</td>
<td>CTX,DX,VP-16</td>
<td>22 Phase II</td>
<td>27</td>
<td>50</td>
<td>n.d.</td>
<td>n.d.</td>
<td></td>
</tr>
</tbody>
</table>

Table 5. CTX, cyclophosphamide; DX, doxorubicin; mOS, median overall survival; mPFS, median progression free survival; n.d., not determined; VCR, vincristine; VP16, etoposide; Modified from: Yamanaka R. Oncol Rep 2009;22:1269-1276 with permission from Spandleos Publications.
3.2 Second-line chemotherapy (Table 6)
SCLC relapse may also require systemic chemotherapy, which showed efficacy in 7 small phase II studies (83-89) with chemotherapy as salvage treatment after failing systemic chemotherapy and WBRT. Response rates are generally lower and survival is decreased in patients who receive chemotherapy for brain metastases after failure following radiotherapy. Postmus et al. (83) reported a response rate of 43% in the brain after high-dose etoposide. Groen et al. (84) reported a response rate of 40% with carboplatin and Postmus et al. (85) reported a response rate of 42% with a single agent, teniposide. The response rates of the primary tumor are not given in these reports. Chen et al. (89) reported a high response rate of 65% with a combination of carboplatin and irinotecan. In an analysis by Schuette et al. (86) and Korfel et al. (88), response rates for brain metastases of 50% and 33%, respectively, were achieved with topotecan. In both, the cerebral response rate was superior to the response rate of the primary tumor, probably because the intact BBB during the first treatment round protected tumor cells of the brain metastases. However, the severe adverse events associated with these regimens would be difficult to tolerate for pretreated patients who had already received radiation and multiple regimens of myelosuppressive chemotherapy. Treatment-related mortality was observed in 7 of 13 patients treated with high-dose etoposide (83) and in 8 of 80 patients treated with teniposide (85).

<table>
<thead>
<tr>
<th>Author</th>
<th>Regimen</th>
<th>No. of patients</th>
<th>Study design</th>
<th>Response rate (%)</th>
<th>Disease stabilization (%)</th>
<th>mPFS (Month)</th>
<th>OS (Month)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Postmus PE</td>
<td>HD-VP16</td>
<td>23</td>
<td>Phase II</td>
<td>43</td>
<td>52</td>
<td>n.d.</td>
<td>8</td>
</tr>
<tr>
<td>Groen H</td>
<td>CBDCA</td>
<td>20</td>
<td>Phase II</td>
<td>40</td>
<td>60</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>Postmus PE</td>
<td>Teniposide</td>
<td>80</td>
<td>Phase II</td>
<td>33</td>
<td>47.5</td>
<td>4.8</td>
<td>2.9</td>
</tr>
<tr>
<td>Schuette W</td>
<td>Topotecan</td>
<td>22</td>
<td>Phase II</td>
<td>50</td>
<td>82</td>
<td>n.d.</td>
<td>6</td>
</tr>
<tr>
<td>Postmus PE</td>
<td>Teniposide</td>
<td>60</td>
<td>Phase III</td>
<td>22</td>
<td>43</td>
<td>4.5</td>
<td>3.2</td>
</tr>
<tr>
<td>Korfel A</td>
<td>Topotecan</td>
<td>30</td>
<td>Phase II</td>
<td>33</td>
<td>60</td>
<td>3.1</td>
<td>3.6</td>
</tr>
<tr>
<td>Chen G</td>
<td>CBDCA, CPT-11</td>
<td>15</td>
<td>Phase II</td>
<td>65</td>
<td>86</td>
<td>n.d.</td>
<td>6</td>
</tr>
</tbody>
</table>

Table 6. CBDCA, carboplatin; CPT-11, irinotecan; mOS, median overall survival; mPFS, median progression free survival; n.d., not determined; HD-VP16, high dose etoposide

Temozolomide shows low response rates when used alone. Ebert et al. (90) reported a case of a patient with SCLC with recurrent brain metastases who was treated with temozolomide and oral etoposide. This regimen was well tolerated and resulted in dramatic, durable responses. Combining temozolomide with other chemotherapeutic agents represents a promising strategy for treating patients with brain metastases from SCLC.

3.3 Chemotherapy plus whole-brain irradiation
Postmus et al. (87) reported a phase III study where 120 SCLC patients with brain metastases were randomized to receive teniposide with or without WBRT. Combined
treatment produced a 57% response rate, and teniposide alone produced a 22% response rate. Combined treatment produced a longer TTP, but both regimens produced similar clinical responses outside the brain, median survival times (median survival 3.5 and 3.2 months, respectively) and symptomatic improvement. Further studies are needed to compare combinations of WBRT with chemotherapy.

4. Discussion

The impairment of physical, cognitive, and affective function that accompanies most brain metastases is highly distressing and can be seen as a "loss" of the patient even before death. Improved treatment of overt brain metastases may have palliative value and eradication of microscopic brain disease may cure patients already cured in other sites. Assumptions about BBB penetration and chemotherapy resistance have limited the use of chemotherapy for treatment of brain metastases. Small, lipid-soluble molecules can penetrate the normal BBB barrier, but large, hydrophilic molecules cannot. Furthermore, high levels of the multidrug transporter, P-gp, are expressed in the endothelial cells of brain capillaries. P-gp actively prevents drugs from passing through the BBB (91). However, macroscopic metastases, relapsed disease, and radiation therapy can disrupt the BBB (92), as shown via magnetic resonance imaging (MRI) or computed tomography (CT) of intravenous contrast inside intracerebral lesions. In addition, the concentration of chemotherapy drugs, including platinum, is similar in intracerebral and extracerebral tumors (5). Cytostatics unable to penetrate the BBB produce comparable response rates for cerebral metastases and systemic disease, and adding BBB-penetrating drugs such as procarbazine, nitrosoureas, or methotrexate to a standard combination regimen did not improve the CNS relapse frequency (93,94). The chemosensitivity of the primary tumor is the major determinant of the response to systemic treatment for brain metastases (92,95), although asymptomatic brain metastases may have lower responses than systemic tumors to systemic chemotherapy (82).

Dexamethasone and enzyme-inducing anti-epileptic drugs (EIAEDs) can induce cytochrome p450 3A isoenzymes, including CYP3A4, which metabolizes chemotherapeutic agents (96,97) including paclitaxel, irinotecan, vinorelbine, cyclophosphamide, doxorubicin, etoposide, ifosfamide, teniposide, erlotinib, and gefitinib. Therefore, co-administration of EIAEDs or dexamethasone may increase the metabolism of chemotherapeutic agents, lower plasma concentrations, and reduce efficacy.

Response and survival rates are generally lower after chemotherapy for brain metastases following radiotherapy failure (84). Combination regimens also produce side effects that would be difficult to tolerate after radiation or multiple regimens of myelosuppressive chemotherapy. Oral agents such as gefitinib, erlotinib, and temozolomide were well tolerated even in pretreated patients, confirming their favorable adverse event profile. In a molecularly selected population with brain metastases, these agents can produce high response rates. Brain metastases resulting from both NSCLC and SCLC are susceptible to systemic chemotherapy, with cerebral response rates similar to primary tumor responses, even in second-line treatment. Clinical conditions such as a chemotherapy-sensitive primary tumor, no prior chemotherapy, or the presence of systemic metastases should indicate the use of chemotherapy. The brain is rarely the sole site of metastases in lung cancer, and patients receiving cranial irradiation alone often die of extra-cranial tumors rather than cerebral metastases. Chemotherapy can control other disease sites and is generally better tolerated than
WBRT. Chemotherapy should be initiated before WBRT because chemotherapy cannot be given for 1 month after WBRT and concomitant WBRT/chemotherapy is more toxic. Combinations of these therapeutic modalities for the management of brain metastases require further testing in randomized phase III studies. Because of the short survival times, the late effects of cranial irradiation such as dementia may be underestimated because they do not usually present until months or years after treatment. Kristensen et al. (98) showed response rates of 76% in primary brain metastases from SCLC but only 43% in relapsed metastases, similar to other SCLC metastatic sites. Chemotherapy has a clearer therapeutic impact in SCLC than NSCLC. Thus, chemotherapy should be incorporated into the management of brain metastases as part of a multimodal treatment concept.

First-line chemotherapy can be performed in patients with asymptomatic or minor neurological symptoms or other metastatic sites, as well as for relapses after radiotherapy or systemic chemotherapy. The main goal of cytostatic therapy is palliation, with clinical improvement and brief, limited duration of high-dose steroid treatments critical to this palliation. The inclusion of patients with brain metastases from lung cancer in prospective trials of new therapeutic agents or combinations should be pursued.

5. References


Brain Tumors: Current and Emerging Therapeutic Strategies focuses on tumor models, the molecular mechanisms involved in the pathogenesis of this disease, and on the new diagnostic and treatment strategies utilized to stage and treat this malignancy. A special section on immunotherapy and gene therapy provides the most up-to-date information on the pre-clinical and clinical advances of this therapeutic venue. Each chapter in Brain Tumors: Current and Emerging Therapeutic Strategies is authored by international experts with extensive experience in the areas covered.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
